Status: Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Pulmovant, Inc.Updated: Apr 22, 2026Locations: 1
Eligibility criteria
Participants willing and able to provide informed consent [+6]
Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related... [+5]